• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan+
  • Wellness
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan+
  • Wellness
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Pembrolizumab reduces disease recurrence in completely resected stage IIB/IIC melanoma

byTeddy Guo
July 12, 2022
in StudyGraphics
Reading Time: 1 min read
0
Share on FacebookShare on Twitter

Click to read this study in The Lancet Oncology.

RELATED REPORTS

Nivolumab does not improve survival in patients with advanced renal cell carcinoma with progression after immune checkpoint inhibitors

Perioperative pembrolizumab improves survival in resectable early-stage non-small cell lung cancer

Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors

Tags: cutaneous melanomadermatologyimmunotherapymelanomaPembrolizumabskin cancer
Previous Post

5-day versus 10-day course of remdesivir in patients with severe COVID-19 [Classics Series]

 Next Post

Use of soft bandage is comparable to rigid immobilization for distal radius torus fractures in children

RelatedReports

Radiographic surrogates may predict tumor-specific survival in renal carcinoma
Chronic Disease

Nivolumab does not improve survival in patients with advanced renal cell carcinoma with progression after immune checkpoint inhibitors

October 30, 2024
Lessons from real-world implementation of lung cancer screening
Chronic Disease

Perioperative pembrolizumab improves survival in resectable early-stage non-small cell lung cancer

October 17, 2024
Sorafenib increases progression-free survival in patients with desmoid tumors
Chronic Disease

Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors

October 1, 2024
Quick Take: Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN)
Pharma

Adaptimmune’s Afami-cel is the first FDA-approved T-cell receptor therapy for synovial sarcoma

September 30, 2024
Next Post
Open carpal tunnel release provides long-term symptom relief

Use of soft bandage is comparable to rigid immobilization for distal radius torus fractures in children

Quick Take: Impact of scribes on emergency medicine doctors’ productivity and patient throughput: multicentre randomised trial

Methoxyflurane a superior analgesic to traditional practices for prehospital trauma

Probiotics improve colic, reduce GI disorders in infants

Multispecies probiotic reduces overall risk of diarrhea in antibiotic-treated children

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Transcranial direct current stimulation with repetitive transcranial magnetic stimulation effective for depression
  • Kidneys from donors with HIV have good safety outcomes in persons with HIV
  • Stereotactic body radiotherapy is noninferior to hypofractionated radiotherapy for localized prostate cancer
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Career
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.